Contineum Therapeutics Appoints John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics, Inc. (NASDAQ: CTNM), a biopharmaceutical company in the clinical stage of development, has announced the appointment of John Healy as its new General Counsel & Corporate Secretary. Contineum is renowned for its work in developing innovative, oral small molecule therapies aimed at treating conditions related to neuroscience, inflammation, and immunology (NI&I).

John Healy brings over twenty years of legal expertise to Contineum. His extensive background includes working at prestigious law firms and serving as General Counsel for public companies in the biotechnology sector. Healy's last role was as General Counsel & Corporate Secretary at Tyra Biosciences, Inc. There, he was a key part of the executive management team and steered the company through its Initial Public Offering (IPO) in late 2021. Throughout his career, Healy has been a legal consultant for numerous companies, providing executive-level legal counsel through various stages of corporate development, including research, product formulation, manufacturing, and public offerings.

Carmine Stengone, Chief Executive Officer of Contineum, expressed enthusiasm about Healy's appointment. "John will be a tremendous asset as a member of our leadership team and will provide valuable guidance as we continue our next steps of growth towards becoming a leading biopharmaceutical company," he stated.

Healy's career began at top national law firms, including Brobeck, Phleger & Harrison, Clifford Chance, and Latham & Watkins. He holds a Juris Doctor degree from the University of San Diego School of Law and a Bachelor of Arts from the University of California, Berkeley.

Upon his appointment, John Healy commented, "I’m thrilled to join Contineum at this exciting time. The Contineum team has made great progress with its internally-developed platform for NI&I conditions and I look forward to working with the team to help guide the company to its next phase of growth."

Contineum Therapeutics focuses on discovering and developing novel therapies for NI&I indications that have high unmet needs. The company aims to target specific biological pathways linked to clinical impairments, believing that modulating these pathways can significantly impact disease progression. Contineum's pipeline includes several internally-developed programs to address multiple NI&I disorders. Notably, the company is advancing PIPE-791, an LPA1 receptor antagonist, and PIPE-307, a selective inhibitor of the M1 receptor, through clinical trials. PIPE-791 has completed a Phase 1 trial, and ongoing development focuses on idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis. PIPE-307 is in a Phase 2 trial for relapse-remitting multiple sclerosis, with a trial for depression slated for 2024. This project is being developed in collaboration with Johnson & Johnson Innovative Medicines.

Based in San Diego, Contineum Therapeutics continues to push the boundaries of biopharmaceutical research and development, aiming to bring effective treatments to market for those suffering from complex medical conditions related to neuroscience, inflammation, and immunology.